Where ER-100 stands: from IND clearance to the first human data, and the steps the registry lists next
Three people with glaucoma received one intravitreal dose of ER-100, and Life Biosciences reports no serious adverse events through Day 56.
The company also reports visual field improvements in two of the three, in a study built mainly to test safety, with vision as a secondary measure.
Life Biosciences reported the first human data for ER-100 on October 8, 2026. ER-100 is a gene therapy that delivers three reprogramming genes to the eye, switched on by an oral drug. The study is open-label, has no control arm and was designed to test safety.
What Life Biosciences reported
Life Biosciences reported interim Phase 1 data from 3 participants with open angle glaucoma. Each received one intravitreal injection of ER-100 at Dose Level 1, plus daily oral doxycycline. No dose-limiting toxicities, adverse events of special interest or serious adverse events were reported through Day 56.
The company says all reported adverse events were related to the procedure, the steroid or pre-existing conditions, and were not directly associated with ER-100. The trial's safety monitoring board (DSMB) recommended moving to Dose Level 2 in glaucoma. So the next result that changes the risk picture is safety at the higher dose, not this vision signal.
The data were presented at Eyecelerator @ AAO 2026 in New Orleans on October 8. Life Biosciences announced FDA clearance of the IND on January 28, 2026, and the company announced its first dosed participant on June 9.
The readout, in short
- Trial: NCT07290244, a non-randomized, open-label Phase 1 study.
- Participants: 3 people with open angle glaucoma.
- Dose: one intravitreal injection at Dose Level 1 (2×1011 vg), with daily oral doxycycline.
- Safety to Day 56: no dose-limiting toxicities, adverse events of special interest or serious adverse events reported.
- Vision signal: Humphrey Visual Field improvements in 2 of 3 participants at Day 56.
- Next: the DSMB recommended escalation to Dose Level 2 (6×1011 vg).
The DSMB recommended a dose 3 times higher next, so Dose Level 2 is the next tolerability test.
How ER-100 works
ER-100 delivers three genes, OCT4, SOX2 and KLF4 (OSK), by one intravitreal injection. The company calls its approach partial epigenetic reprogramming, using three of the four Yamanaka factors. The registry states that ER-100 does not alter the participant's existing genes.
Oral doxycycline switches on OSK expression and is given for 8 weeks, so expression is meant to depend on a daily oral drug taken for a fixed period. An oral prednisolone taper is given to lower the risk of inflammation from the immune response to AAV2.
The company notes that non-arteritic anterior ischemic optic neuropathy (NAION) has no approved treatments. It says its preclinical studies restored visual function in animal models, without naming the disease models.
How to read the visual field signal
Humphrey Visual Field results improved in 2 of 3 participants at Day 56. In each of those two, at least 28% of test points improved by more than 4 dB. That is a point-by-point count, not a whole-field average.
The registry lists Humphrey Visual Field mean deviation as both a safety outcome and a secondary efficacy outcome. The release does not report mean deviation. The data cover 3 participants, open-label dosing and no control arm.
2 of 3 participants showed visual field improvements at Day 56, in a study designed to test safety.
What comes next
The registry lists an estimated 18 participants: 12 with open angle glaucoma and 6 with NAION. Glaucoma dose escalation comes first, followed by a NAION expansion.
At each new dose level, one sentinel participant is monitored for 28 days, then the DSMB reviews before two more are dosed. Primary outcomes are safety measures to Day 56 and Day 112, and participants are followed for up to 5 years. That per-level wait sets the pace toward the May 2027 primary completion estimate.
Primary completion is estimated for May 2027, and study completion for March 2032. Life Biosciences said its $80 million Series D in April will fund operations into the second half of 2027, including Phase 1 completion.
What this means for a CGT program
GTC analysis: on regulatory design, the doxycycline switch reads as a safety control. Expression is designed to depend on an oral drug given for a fixed period. A reprogramming-factor program should expect its regulator to ask how expression is stopped, and how fast.
GTC analysis: on protocol design, ER-100 was given with an oral prednisolone taper, and the company attributes the reported adverse events to the procedure, the steroid or pre-existing conditions. So the tolerability reported so far is for ER-100 given with a steroid taper, not ER-100 alone. An intravitreal AAV program choosing its own immunosuppression should expect its safety data to be read the same way.
GTC analysis: on timeline, the DSMB recommendation to open Dose Level 2 was reported on October 8, about seven months before the May 2027 primary completion estimate. Each further dose level needs at least 28 days of sentinel follow-up and a DSMB review before it fills. How many dose levels fit in that window is the timeline question to track.
GTC analysis: on budget, the stated runway into the second half of 2027 sits close to the May 2027 primary completion estimate. If enrollment slips, the funding margin narrows. Investors should watch the pace of dose escalation more than this early vision signal.
If you have run an ocular AAV trial or a dose-escalation safety review, GTC's Expert Network matches drug development experts like you to paid consulting work: join free.
Frequently asked questions
What did Life Biosciences report for ER-100?
On October 8, 2026, Life Biosciences reported interim Phase 1 data from 3 participants with open angle glaucoma. One intravitreal injection at Dose Level 1, plus daily oral doxycycline, was well tolerated through Day 56. No dose-limiting toxicities, adverse events of special interest or serious adverse events were reported.
What is ER-100?
ER-100 is a gene therapy that delivers three reprogramming genes, OCT4, SOX2 and KLF4, by one intravitreal injection. Oral doxycycline switches on their expression and is given for 8 weeks. The trial registry states that ER-100 does not alter the participant's existing genes.
Does the data show that ER-100 improves vision?
Not yet: Humphrey Visual Field results improved in 2 of 3 participants at Day 56. But the study is open-label, has no control arm and was designed to test safety. The company itself calls the visual field observations preliminary.
What happens next in the ER-100 trial?
The DSMB recommended escalation to Dose Level 2 in open angle glaucoma. The registry lists an estimated 18 participants, 12 with glaucoma and 6 with NAION. Primary completion is estimated for May 2027.
How is the ER-100 program funded?
Life Biosciences raised an $80 million Series D in April 2026. The company said it will fund operations into the second half of 2027, including completion of the Phase 1 trial.
Sources
- Life Biosciences Announces First-in-Human Data from Ongoing Phase 1 Trial Evaluating ER-100 in Optic Neuropathies - Life Biosciences, news release, October 8, 2026.
- Life Biosciences to Present First-in-Human Data from Ongoing Phase 1 Trial Evaluating ER-100 in Optic Neuropathies at Eyecelerator 2026 - Life Biosciences, news release, October 1, 2026.
- Life Biosciences Announces First Patient Dosed in Phase 1 Trial of ER-100 for Optic Neuropathies - Life Biosciences, news release, June 9, 2026.
- Life Biosciences Announces FDA Clearance of IND Application for ER-100 in Optic Neuropathies - Life Biosciences, news release, January 28, 2026.
- Life Biosciences Secures $80 Million Series D Financing - Life Biosciences, news release, April 8, 2026.
- NCT07290244: Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy - ClinicalTrials.gov, study record.
Join the GTC Expert Network
Independent Experts
Independent experts in cell & gene therapy: share knowledge, help build a report, or contribute quietly. Build authority and get called for paid consulting work. Join free.
Early R&D Experts
Early R&D ExpertsContribute target validation, vector engineering, or transgene design expertise. Get matched to paid consulting work through content you help create.
Join FreeCMC Experts
CMC ExpertsContribute scale-up, tech transfer, or GMP manufacturing expertise. Get matched to paid consulting work through content you help create.
Join FreeRegulatory Affairs Experts
Regulatory Affairs ExpertsContribute IND/BLA strategy or regulatory liaison expertise. Get matched to paid consulting work through content you help create.
Join FreeCommercial & Strategy Experts
Commercial & Strategy ExpertsContribute due diligence, licensing, or market access expertise. Get matched to paid consulting work through content you help create.
Join FreeEnabling Technology Experts
Enabling Technology ExpertsContribute bioprocessing hardware, analytical tooling, or supply-chain expertise. Get matched to paid consulting work through content you help create.
Join FreeAI Transformation Experts
AI Transformation ExpertsContribute agentic workflow, LLM, or AI-driven vector design expertise. Get matched to paid consulting work through content you help create.
Join FreeIndustry Representatives
Industry professionals in cell & gene therapy: de-risk your pipeline with expert input on demand, exactly when your program needs it. Join free.
Drug Developers
Drug DevelopersFounders, CSOs, VPs of R&D
Practical guides spanning vector design through commercialization, plus direct access to the expert network that wrote them.
Join FreeInvestors / VCs
Investors / VCsVC Fund Managers, Family Offices, Angels
Due diligence frameworks and strategic intelligence for evaluating CGT assets, from experts who do this diligence for a living.
Join FreeTechnology Developers
Technology DevelopersFounders, Licensing & Commercial Leads
IP protection and platform strategy guides for enabling technologies, plus the network that built them.
Join FreeCDMOs / CROs
CDMOs / CROsBD, Operations & Technical Leads
Partner selection, vendor evaluation, and operational excellence guides, sourced from the CGT organisations that use them.
Join FreeVendors / Suppliers
Vendors / SuppliersCommercial & Technical Leads
Market intelligence and partnership strategies for supply chain companies serving cell and gene therapy.
Join FreeStrategy Consultants
Strategy ConsultantsConsultants, Market Access Advisors
Spot the problems before they cost your clients - join the network that shapes what GTC covers next.
Join FreeAI Transformation Partners
AI Transformation PartnersAI/ML Consultancies, Digital Transformation Firms
AI education, implementation, and consulting for operational excellence in cell and gene therapy - for companies building or buying AI capability.
Join FreeWhere the analysis comes from. Industry teams get expert input on demand; independent experts build authority and get called for paid consulting work.
See more of our work in Google Search
Google lets you pick the sites you want to see more often in Top Stories. Add Gene Therapy Consultancy to your list, and our daily gene therapy news will show up higher for you.